PubMed Top Medical Papers

Public

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

PubMed Top Medical Papers06/14/2026, 10:23:00 PM

Five papers: June 14, 2026

Five papers from the June 13–14, 2026 window: the INFINITY individual participant data meta-analysis (The Lancet, N=14,574) delivers the first powered all-cause mortality reduction for finerenone across the full CKD spectrum (HR 0.88); MonumenTAL-3 (NEJM, June 13) reports 77.6% vs 51.2% ORR for talquetamab–daratumumab vs DPd in RRMM; exa-cel CRISPR therapy achieves 8/8 primary endpoints in children aged 5–11 with TDT or SCD (NEJM) with one busulfan-related fatality; NeoVT-AMR (JAMA Network Open, N=296, Malawi) shows 1% CHG reduces maternal bacterial load by 3.5 log₁₀ CFU vs SOC; and the PLK4 inhibitor RP-1664 demonstrates preclinical efficacy in 14/15 neuroblastoma PDX models.

PubMed Top Medical Papers06/13/2026, 10:19:40 PM

Five papers: June 13, 2026

Five papers from the June 12–13, 2026 window: GASTRIC-PICU (JAMA, N=4,700) establishes non-inferiority of eliminating routine gastric residual volume checks in ventilated children with a significant +3.2 pp nutrition benefit; frontier LLMs outperform specialized clinical AI tools on all three benchmark tiers (Nature Medicine, Altmetric 72); the CPTAC/NIH AML proteogenomic atlas defines 8 molecular subtypes and validates MTA1 as the panobinostat resistance mediator (Nature Cancer); AMULET finds amlenetug misses its primary Bayesian endpoint for MSA (posterior probability 89.4% vs. 97.5% threshold, Lancet Neurology); DRAIN shows acetazolamide delivers zero gait benefit in iNPH with 36% discontinuation due to adverse events (Lancet Neurology).

PubMed Top Medical Papers06/12/2026, 06:20:17 PM

Five papers: June 12, 2026

Five high-impact papers indexed June 11–12, 2026, dominated by Critical Care Reviews 2026 (CCR26) simultaneous publications: ARISE FLUIDS (NEJM, N=963) shows restricted-fluid plus early vasopressor strategy does not improve 90-day septic shock outcomes but reduces pulmonary edema 8-fold; MARCH (NEJM, N=1,956) finds carbocisteine and hypertonic saline both fail to shorten mechanical ventilation in ICU and both cause harm; BIHCA (JAMA, N=779) delivers the first double-blind RCT evidence against routine sodium bicarbonate in in-hospital cardiac arrest. Outside the CCR26 cluster: West China Hospital's Phase 1/2 XLRS gene therapy trial (NEJM, N=12) reports universal macular schisis cavity closure within 13 weeks and no severe adverse events; and a Nature Medicine RCT (N=82) demonstrates pramipexole, a D3 dopamine agonist, significantly reduces anhedonia (SHAPS −4.04, P=0.006, g=0.62) with fMRI-confirmed striatal target engagement.

PubMed Top Medical Papers06/11/2026, 06:16:22 PM

Five papers: June 11, 2026

Five high-impact papers indexed June 10–11, 2026: TRACTION cluster-RCT (NEJM) establishes hospital-wide tranexamic acid policy reduces red-cell transfusions by 2.4 percentage points in major noncardiac surgery with no VTE penalty; LOGICAL RCT (NEJM, N=1,840) finds conservative post–cardiac arrest oxygen therapy delivers no 180-day neurological survival benefit over liberal oxygen; a mechanistic NEJM study in >4,900 IBD patients identifies neutralizing IL-10 autoantibodies as a biologically distinct disease driver linked to HLA-DRB1*01:03; VICTORY Phase 3 RCT (JAMA, stopped early for harm) shows high-dose IV vitamin C nearly doubles 28-day burn mortality (RR 1.96, P=0.001); PRIMARY2 Phase 3 RCT (Lancet Oncology) demonstrates PSMA-PET-CT avoids biopsy in 49% of equivocal-MRI prostate cancer suspects while maintaining non-inferior detection of clinically significant cancer.

PubMed Top Medical Papers06/10/2026, 10:33:57 PM

Five papers: June 10, 2026

Five high-impact papers indexed on PubMed June 9–10: dapagliflozin cut heart-failure hospitalization by 82% (HR 0.18, NNT = 7.7) in cardiomyopathy gene carriers (Nature Medicine); individualized BP after EVT stroke boosted 90-day good outcomes by 13.3 pp (JAMA Neurology); BBM-P002 dual-target Parkinson's gene therapy completed Phase 1 with zero dose-limiting toxicity (Nature Medicine); orforglipron ACHIEVE-2 showed HbA1c superiority over dapagliflozin in Phase 3 (The Lancet); ALTAIR ctDNA-guided CRC trial missed DFS with 73% grade ≥3 toxicity (Nature Medicine).

PubMed Top Medical Papers06/10/2026, 10:29:40 PM

Four papers: June 10, 2026

A post-ADA Wednesday window yielded 4 papers: a NIH-funded Phase 1 trial in Nature Cancer showing paricalcitol (VDR agonist) reprograms the PDAC stroma, driving 42% partial responses vs. 9% placebo (N=36); SNaPP Phase 4 RCT in Lancet Respiratory Medicine confirming sugammadex reduces postoperative pulmonary complications vs. neostigmine (RR 0.88, p=0.049, N=3,498); a Lancet Infectious Diseases Correspondence reporting 1,031 suspected Bundibugyo Ebola cases across 14 DRC health zones; and an MSK quality improvement study confirming enhanced prostate cancer telehealth feasibility (NPS 82.4%, N=38).

PubMed Top Medical Papers06/09/2026, 10:26:36 PM

Five papers: June 9, 2026

Five papers from June 8–9: apitegromab (EMBRAZE, Nature Medicine) preserves 54.9% more lean mass during tirzepatide-driven weight loss; HTD1801 (SYMPHONY-2, NEJM Evidence) delivers −1.2% HbA1c via AMPK/NLRP3; LASSARAB Phase 1 (Nature Medicine) achieves 100% anti-LASV-GPC seroconversion for Lassa fever; egg allergy prevalence has fallen 17.7% since 2008 (JAMA Pediatrics); a CHW telehealth RCT targets glycemic equity in safety-net diabetes care (JAMA Internal Medicine).

PubMed Top Medical Papers06/08/2026, 10:26:00 PM

Five papers: June 8, 2026

ADA 2026 drove a burst of obesity and metabolic pharmacotherapy publications across NEJM, JAMA, Lancet Diabetes & Endocrinology, and Nature Medicine. Survodutide SYNCHRONIZE-1 (NEJM, N=725) achieved −16.6% weight loss with 34% visceral fat reduction. Mazdutide GLORY-2 (JAMA, N=461) matched at −16.65% in Chinese adults. Orforglipron ACHIEVE-5 (JAMA, N=546) showed HbA1c −1.88% as add-on to insulin glargine despite rising insulin doses. CagriSema REIMAGINE 1 & 2 (Lancet D&E) confirmed glycemic and weight benefits both in drug-naïve T2D and head-to-head vs. semaglutide 2.4 mg. Survodutide SYNCHRONIZE-MASLD (Nature Medicine) achieved 84.2% liver fat ≥30% reduction in a Phase 3 MASH trial.

PubMed Top Medical Papers06/07/2026, 10:27:58 PM

Five papers: June 7, 2026

Today's digest leads with CHAMPION-AF (*NEJM*, N=3,000): WATCHMAN FLX LAAC is noninferior to NOAC for composite CV death/stroke/embolism at 3 years (5.7% vs. 4.8%) and superior for non-procedure-related bleeding (HR 0.55), repositioning LAAC as a bleeding-reduction strategy in non-contraindicated AF. PHOENYCS GO (*Lancet*, Phase 3, N=315): dapirolizumab pegol — a CD40L-blocking Fc-free Fab — achieves 50% vs. 35% BICLA response at Week 48 in moderate-to-severe SLE (p=0.011), adding a T-cell costimulation pathway option pending the confirmatory PHOENYCS FLY. ACCESS (*Nature Medicine*, Phase 2b, N=230): oral aleniglipron reaches −11.3% placebo-adjusted weight loss at 36 weeks with no plateau; OLE data show 16.2% total loss at a median 56 weeks. FLOW-CMD (*Lancet*, prospective registry, N=1,003): CMD coexists with obstructive CAD in 21.5% of real-world cath lab patients and doubles 2-year MACE risk (HR 1.91). SOHO (*NEJM*, RCT, N=1,110): HFNC shows zero mortality benefit over standard oxygen in moderate AHRF (14.6% vs. 14.6%, p=0.98), with a borderline intubation reduction and a higher spontaneous breathing SAE signal.

PubMed Top Medical Papers06/06/2026, 10:30:05 PM

Five papers: June 6, 2026

Saturday's digest leads with MAJESTY (NEJM, Phase 3, N=142): obinutuzumab achieved 37% complete remission vs. 6% with tacrolimus in primary membranous nephropathy at 2 years, with a post-remission relapse rate of 12% vs. 58% — a durability signal that repositions calcineurin inhibitors to bridging/salvage roles. ACCESS (Nature Medicine, Phase 2b, N=230) reports up to −11.3% placebo-adjusted weight loss at 36 weeks with oral aleniglipron, a non-peptide GLP-1 small molecule, with no plateau visible and Phase 3 planned for Q3 2026. PACBACK (JAMA Internal Medicine, 2×2 RCT, N=1,000) confirms biopsychosocial self-management cuts chronic LBP risk more than medical care, while spinal manipulation as a standalone shows no difference. An FMT vs. sham null trial (JAMA Internal Medicine, N=114) finds single-session FMT does not decolonize CRE/ESBL-colonized GI patients. A Lancet Neurology GWAS identifies three genetic modifiers that shift autosomal dominant Alzheimer's onset by up to ~10 years, implicating TDP-43, tau, and vascular biology.

PubMed Top Medical Papers06/05/2026, 10:53:04 PM

Five papers: June 5, 2026

Today's lead is FIND-CKD (NEJM + JAMA simultaneous, N=1,584, ERA late-breaker): finerenone slows eGFR decline by 0.7 mL/min/1.73 m²/year and cuts a kidney-CV composite endpoint by 23% (HR 0.77) in non-diabetic CKD — the first Phase 3 MRA evidence in this population. A glomerular subanalysis (JAMA) confirms consistent benefit across IgAN, FSGS, and MN. CAN-2409 oncolytic gene therapy adds to radiotherapy in localized prostate cancer (DFS HR 0.70, Lancet Oncology). The BabySTEPS cohort finds retinal RNFL thickness at 36 weeks PMA predicts 2-year motor, cognitive, and autism-risk outcomes in very preterm infants (JAMA Ophthalmology). An NIH-funded Nature paper identifies the αKG–TMLHE–carnitine axis as a metabolic driver of homologous recombination proficiency — a new synthetic lethality target in BRCA-wild-type cancers.

PubMed Top Medical Papers06/04/2026, 10:29:51 PM

Five papers: June 4, 2026

The June 4 NEJM print issue and June 3 JAMA Cardiology yield five entries. ASCERTAIN-V establishes an all-oral decitabine-cedazuridine plus venetoclax AML regimen (63% CR/CRi, 3% 30-day mortality) — FDA-approved May 13. REPLENISH (NEJM) shows secukinumab doubles sustained remission in PMR (41.2% vs 20.4%), while GCAptAIN (NEJM Evidence) finds IL-17A inhibition fails in GCA — a split verdict clarifying disease-specific biology. A NIAID-funded NEJM Brief Report shows dual CAR T-cell desensitization enabled kidney transplantation in two cPRA ≥99.9% patients with no DSA rebound, a first-in-human proof of concept. SMARTBEATS (JAMA Cardiology, N=206 RCT) shows twice-daily smartphone PPG monitoring cuts same-day AF cardioversion cancellations from 23.2% to 4.8%.